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Abstract 
A key component of informed consent to participate in research is the understanding that 
research is not the same as treatment and that scientific goals have priority over 
therapeutic ones. However, studies have found many research participants do not 
understand these important differences between research and treatment, a phenomenon 
termed therapeutic misconception (TM). The problem addressed in this project was 
research nurses’ lack of education regarding the existence and concepts of TM, and their 
struggles to assess and address research participants’ TM of clinical trials. Matutina’s 
conceptual model of TM was used to guide this project. The purpose of this project was 
to develop an educational program that prepares registered nurses to assess clinical trials 
participants for TM and correct any misunderstandings. The educational program 
included concepts related to TM, guidance on recognizing TM, strategies to correct 
participant misunderstanding, and assessments of nurses’ understanding of related 
concepts and strategies. The products of this project include the program with an 
implementation plan and an evaluation plan that outlines short- intermediate- and long- 
term plans for evaluating effectiveness of this program. For both short and intermediate-
term evaluation, outcomes will be measured using a pre and post survey. The long-term 
evaluation of the educational program was designed as a study to measure TM among 
research participants comparing data before and after nurses receive TM education. 
Refining the standard education of TM for registered nurses can serve both to improve 
protection of trial participants and to clarify the informed consent process, ultimately 
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Section 1: Nature of the Project 
Introduction 
Studies have found that some research participants do not understand important 
differences between research and treatment, a phenomenon called therapeutic 
misconception (TM) (Applebaum, Roth, & Lidz, 1982 and Barrett, 2005). TM arises 
from the conviction that the purpose of clinical medicine and clinical research is to 
benefit the patient and that a physician will always act according to what is the best 
medical care for the patient (Applebaum, Anatchkova, Albert, Dunn, & Lidz, 2012). 
When recruiting for clinical trials, healthcare providers must ensure potential participants  
understand that therapeutic benefit to the individual is secondary to the overriding goal of 
the research study. A key component of informed consent to participate in research is the 
understanding that research is not the same as treatment. Ethicists contend that informed 
consent to participate in research should explain the difference between research and 
treatment in language that the lay person will understand (Applebaum, Roth, & Lidz, 
1982). Applebaum et al. (1982) found that many of the study participants believed they 
were receiving treatment in the form of a medication, based on what was most 
therapeutic to them personally, despite being told by the researchers that they were 
participating in a clinical trial in order to discover scientific knowledge and that they may 
not benefit from participation in the trial. Barrett (2005) stated that “although participants 
are explicitly told that scientific goals have priority over therapeutic ones and 
investigators’ primary interests are in improving treatment options, participants persist in 
believing that they will receive benefit from their involvement in the research” (p. 752).  
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The Nuremburg Code clearly stated that research participation is undertaken 
“without the intervention of any element of force, fraud, deceit, duress, over-
reaching, or other ulterior form of constraint or coercion…” (International Military 
Tribunal, 1949). Black et al. (2013), citing the World Medical Association (1964), 
stated that “the requirement of voluntariness has been confirmed universally over the 
years as an essential element of research participation” (p. 26). The misunderstanding 
of the purpose of research (TM) has the potential to compromise the voluntariness of 
consent by creating a risk-benefit perception by the patient that does not coincide 
with the reality of the trial. Barrett (2005) asserted that “as patient advocates and 
educators, nurses must be able to assess individuals’ understanding to ensure the 
validity of the informed consent process” (p. 752).  
Problem Statement 
TM is a critical problem in research clinical trials (Applebaum et al., 2012). 
Research and therapeutic clinical care involves different standards with regards to the 
treatment of the patient or research subject. The sole purpose of medical therapy is to 
treat an illness or injury and to improve health. The primary purpose of medical research 
is to gain knowledge. The confusion of the two often leads to profound 
misunderstandings on the part of the research subject. The role of nursing in clinical 
research continues to expand and “nurses must develop strategies that provide clinical 
trial patients with a better understanding of the trial they are considering, identify areas of 
misunderstanding and correct them, and assess the outcomes of the informed consent 
process” (Barrett, 2005, p. 752). This project addressed the problem of the research 
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nurse’s education regarding the existence and concepts of TM and the ability to assess 
and correct, if necessary, the research subject’s misunderstanding of the trial. The 
problem addressed in the project was the lack of knowledge among registered nurses 
regarding TM.  
Purpose Statement 
Historically, research on TM has been conducted because of concern that 
participants may misunderstand aspects of trial care that leads them to make decisions 
incompatible with their true preferences and values. Obtaining informed consent, 
permission granted by patients for healthcare services, and knowing the possible 
consequences is an ethical obligation of nurses and other health care providers. 
Registered nurses working with clinical trial participants should (a) understand the 
concepts of TM as well as the potential negative impact on the informed consent process, 
(b) be able to assess clinical trials participants for the influence of TM, and (c) be able to 
correct any misunderstanding the participants may have regarding the benefits and 
purpose of participation in the clinical trial. The purpose of the project was to develop an 
educational program for registered nurses (RNs) on TM.  
Goals and Outcomes 
The goal of the project was to improve RNs’ ability to decrease TM in clinical 
trials. This goal included several objectives to increase the RN’s (a) knowledge of 
therapeutic misconception, (b) skill in assessing the participants understanding of trials, 
and (c) ability to correct the participants misunderstanding of the trial purpose.  In 
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achieving the objectives, the overall goal of the project was achieved. The objectives 
were measured in the evaluation phase using a pre- and post-survey.   
As a component of participation in the program, registered nurses were asked to 
complete a survey before and after the education program in order to gauge their 
knowledge of TM. Measures included the RNs’ (a) knowledge of the existence and 
concepts of TM, (b) knowledge regarding the assessment of participant’s understanding 
of trial, and (c) method of correcting the participant’s misunderstanding of the trial 
purpose.  
Definition of Terms 
Clinical trial: The World Health Organization defined a clinical trial as “any 
research study that prospectively assigns human participants or groups of humans to one 
or more health-related interventions to evaluate the effects on health outcomes” (World 
Health Organization, 2014, para.1).  
Educational Program: A scheduled series of lessons designed to convey the 
knowledge and skills, related to TM, of the clinical trials experts to registered nurses 
inexperienced in clinical trials, through teaching, training and research.  
Expert: Having, involving, or displaying special skill or knowledge derived from 
training or experience (Merriam-Webster on-line Dictionary). 
Informed consent: Informed consent is a process designed for the protection of 
human subjects in research. Ensuring that subjects who participate in research are made 
aware of the experimental nature and that they voluntarily consented to participate is very 
important.  Among the important consideration from the Belmont Report (1979), the 
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“respect-for-persons” principle is the requirement that subjects are given the opportunity 
to decide for themselves if they want to participate in a study after being told that they 
will be subjected to human experimentation. When consent is signed on the false belief 
that the study provides direct benefit of treatment and individual care, informed consent 
is not fully administered.  
Registered nurse: A nurse who has graduated from an accredited school of 
nursing, has passed an exam, and has been registered and licensed to practice by state 
authority (Stedman’s Medical Dictionary, 2002).  
Therapeutic misconception: The definition of TM can be found in Henderson’s et 
al. (2007) statement: 
Therapeutic misconception exists when individuals do not understand that the 
defining purpose of clinical research is to produce generalizable knowledge, 
regardless of whether the subjects enrolled in the trial may potentially benefit 
from the intervention under study or from other aspects of the clinical trial.” (p. 3)  
Assumptions and Limitations 
In this project, I assumed that educating registered nurses working with clinical 
trials patients regarding TM had a positive impact on decreasing the existence and 
prevalence of TM in the research departments of adult oncology. A second assumption 
was that the RN recognized the value in learning about TM as a benefit not only to his or 
her career but more importantly as a benefit to his or her research participants. 
This project was limited by the varied geographical locations of the team 
members, the dependence on technology, and the variance of multiple schedules. The 
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team consisted of clinical trials experts employed at several facilities throughout the state. 
Communication among the team members was accomplished via e-mail, and meetings 
were conducted using telephone conference lines. Conflicting schedules proved to be a 
challenge in scheduling meetings with all team members in attendance.  
This project was further limited by the inability to test whether or not TM was 
actually decreased by educating RNs on the concepts and existence of TM. Because this 
project did not include the perceptions of research participants, the ability of the RN to 
decrease TM could not be measured. Therefore, the outcome of the educational 
intervention was measured in the evaluation stage using the nurse’s perception and self-
reporting.  
Biases 
Risks of bias for this project included program design and evaluation. By design, 
this project’s implementation included a small sample size of registered nurses 
participating in the educational program. In general, the larger the sample size in a 
quantitative study, the more likely the sample will be representative of the population of 
interest (Myers & Hanson, 2002). The educational program should be expanded to 
include larger sample sizes before data can be considered impartial, accurate, and useful.  
As a part of the participation in the educational program, in the implementation 
stage, registered nurses will be asked to complete a survey designed to gauge their 
knowledge of TM. After participating in the educational program, the nurses will be 
asked to complete the same survey. Before and after comparisons will be made to 
evaluate whether or not the program positively affects the nurses’ knowledge of TM, 
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their ability to recognize TM, and their confidence in their ability to correct participants’ 
misconceptions regarding the purpose of research. A pre- and post-test data collection 
tool offers “a measurement of the learning received during the [class] as a result of 
comparing what the student knew before in a pre-test and after in a post-test. The same 
instrument is used to collect data before and after the experience” (Diem, 2002, p. 1). The 
integrity of the data will depend largely on the validity and reliability of the data 
collection tool.    
Relevance to Nursing Practice 
Judkins-Cohn, Kielwasser-Withrow, Owen, and Ward (2013) stated that during 
the past 20 years, there has been an increase in developing policies that ensure the use of 
research and evidence-based practice for both nursing and medicine in the clinical 
setting. With the increase in research activities, more nurses are engaging in research as 
Principle Investigators (PIs) and members of research teams. The 2010 Institute of 
Medicine’s Future of Nursing report recommended that by 2020 there will be a need for 
double the current number of doctoral prepared nurses. Thus, “the result is the creation of 
the dual role of care provider and researcher” (Judkins-Cohn et al., 2013, p. 4199). This 
dual nursing role demands a thorough understanding of the informed consent process. 
This understanding includes the difference between the goals of clinical care and research 
(TM), following research-specific ethics involved in the informed consent process, and 
understanding quality measures of the informed consent process. 
The TM is a serious problem for informed consent in clinical research and 
conflicting desired health outcomes for healthcare providers and patients suggest 
8 
 
implications for nursing practice. Applebaum and Roth (1983) raised the question, “Who 
should have the task of explaining the therapeutic misconception to subjects?” (p. 12). 
Institutional policies typically require that potential participants be approached about 
research by someone known to them and that the consent process must be conducted by 
someone who fully understands the research study. The PI for a research study may also 
be the healthcare professional caring for a potential research participant.  
The PI may be the person most knowledgeable about the research and most 
qualified to approach the potential participant; however, they may not be the best person 
to complete the informed consent process. Because of the potential for TM, there may be 
benefit to having a research study team member who is not the PI involved in the consent 
process (Pranati, 2010). The PI has a responsibility to distinguish between treatment and 
research and to clearly explain the implications for the potential participant.  However, 
even when a PI clearly emphasizes that the goal of the research is not to provide care, 
patients sometimes continue to believe that the research will provide them with direct 
benefit (Pranati, 2010). Pranati (2010) also stated that a solution to this challenging 
situation is to have the research nurse complete the informed consent process after the PI 
has explained the research in detail. The study nurse can then determine whether the 
patient understands the research and his/her willingness to participate outside the direct 
influence of the PI. Clinical trial nurses must communicate information about the nature 
and goals of clinical research, explain the details of the specific study, and assess 




Solid understanding of research ethics requires the clear distinction between 
research and therapeutic treatment. The first principle of The Belmont Report (1979), 
which is the ethical basis for the U.S. federal regulations, is “respect for persons”—
persons have the right to decide for themselves whether to participate in research on the 
basis of information provided about the nature of the trial, potential benefits, and adverse 
effects, and alternative treatments. In order to decrease the incidence of TM, researchers 
must be judicious in their use of the term “treatment” (Banks, 2009). When a study drug, 
study intervention, or investigational therapy is referred to as a treatment, there is an 
increased chance that a potential participant will misinterpret the purpose of the trial. The 
patient-participant who thinks they are receiving individualized therapy when in fact they 
are being treated according to a research protocol cannot give informed consent (Steinke, 
2004).      
Kola and Landis (2004) reported that the average success rate for new drugs was 
11%, ranging from 20% in cardiovascular trials to 5% in oncology trials. They found that 
60% of the time, the reasons that the drugs did not make it to market were efficacy and 
safety. It is very likely in oncology Phase I and II trials that the patient will not benefit, 
and consent language must state this clearly (Kola & Landis, 2004). The mere disclosure 
of risks and benefits in lengthy and legalistic forms may not be sufficient in light of such 
evidence (Barrett, 2005). Evidence has suggested transforming the informed consent 
process from passive disclosure to more active education and interaction with patient 
participants in clinical research (Pranati, 2010). When discussing a participant’s 
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expectations of direct benefit, only the benefits that can be “reasonably expected” should 
be discussed (Banks, 2009). This clarification will help participants understand the 
potential benefits of the research, as well as the alternatives to the research that are 
available. 
Social Change 
The societal response to ethical problems associated with clinical research has 
been the implementation of regulatory laws and policies, including detailed federal 
regulations governing research involving human subjects (Miller, Rosenstein, & 
DeRenzo, 1998). The application of these regulations has led to improved protection of 
the rights and welfare of research participants; however, there remain deficiencies that 
need to be addressed (Miller et al., 1998). Changes to consent procedures should be 
adopted to ensure that all potential participants are aware that their condition and benefit 
is not the priority of the clinical trial (Pranati, 2010). Diligent examination of potential 
research participants should expose truly altruistic reasons for participating in the trial. 
Potential participants should understand and accept that they may not benefit medically 
from participation in a clinical trial.  
Summary 
TM has been seen as presenting an ethical problem because failure to distinguish 
the aims of research treatment from those receiving standard treatment may seriously 
undermine the informed consent of research participants. Although TM is not considered 
a complete failure to obtain informed consent, health care researchers must be confident 
in determining the answers as to why the patient is joining the study and what health 
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benefit they expect to obtain. Because of the potential for TM, there may be benefit to 
having a research study team member who is not the PI involved in the consent process 
(Pranati, 2010). TM may be decreased or alleviated by educating nurses involved in 
research on the existence and concepts of TM, allowing participants a much clearer 
picture of the relative risks and benefits of participation in a clinical trial. 
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Section 2: Review of Literature and Conceptual Framework 
Literature Review 
 Using the Walden Library and other appropriate databases (CINAHL Full 
Text, PubMed, Medline Full Text, and Ovid Nursing Journals Full Text) peer-reviewed 
articles were located for inclusion in this evidence-based project. Although there was an 
effort to use the most current information available, there was no stipulation for years 
searched. Key search terms included therapeutic misconception, informed consent, 
oncology clinical trials, and nursing research communication. The search included major 
authors: Applebaum, Roth, and Lidz. Inclusion criteria consisted of research ethics, 
medical ethics, clinical trials coordinator, and communication in research. The term 
therapeutic overestimation is often times confused with TM and was excluded from 
research criteria.   
Therapeutic Misconception  
 In 1982, Applebaum et al. reported on findings from interviews with 
research patients who documented failure to appreciate the difference between research 
and treatment, labeling the phenomenon “therapeutic misconception.” TM arises from the 
conviction that the purpose of both clinical treatment and clinical research is to benefit 
the patient and that a physician will always act according to what is the best medical care 
for the patient (Applebaum, 2012). In 2007, Henderson et al. reported that “for over three 
decades, bioethics scholarship and research ethics guidelines have identified concerns 
about the boundaries between research and standard clinical care” (p. 1735). Ethicists 
have argued that informed consent to participate in research should include clarification 
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of the differences between these two activities (Applebaum et al., 1982). While a research 
participant may receive good clinical care as a participant in research, clinical care must 
not be confused with clinical research, which is to generate scientific knowledge to 
improve therapy for future patients (Henderson et al., 2007).  
 Meropol et al. (2003) found that a clinical trial cannot be assigned 
therapeutic merit without denying the trial’s scientific merit. One process instrumental in 
alleviating TM is the informed consent process. Informed consent is governed in clinical 
research by three basic elements where the participant (a) is informed about the study 
including risks and benefits, (b) understands the information, and (c) enrolls voluntarily 
(The Belmont Report, 1979). The Code of Federal Regulations (21 C.F.R. Part 50.25) 
requires that the consent form explicitly state that the study involves research and the 
purpose and procedures are experimental. This information is relevant to the current issue 
of the ethical implications of TM. This federal guideline reinforces the scientific focus of 
clinical research. Barrett (2005) claimed that “current methods of obtaining valid 
informed consent may be insufficient to ensure patients understanding of information of 
the proposed trial” (p. 751). The language used for informed consent must not promote 
but reduce TM.  
The problem of TM may extend beyond the informed consent process and cause a 
lack of trust in research as a whole (deMelo-Martin & Ho, 2008). DeMelo-Martin and Ho 
(2008) argued that “the differences between the goals of clinical treatment and research 
are so significant that they ought to be governed by distinct ethical norms” (p. 202). The 
authors indicated that research participants trust the principle investigator in the same 
14 
 
way they trust their treating physician and that this trust is misplaced (de-Melo-Martin & 
Ho, 2008).  Because the protection of patients’ best interests is not a goal of an oversight 
agency deMelo-Martin and Ho further stated that a participant’s trust in research 
oversight agencies is also misplaced. DeMelo-Martin and Ho concluded that under the 
influence of TM, research participants’ trust is misplaced if they trust the researchers and 
oversight agencies to protect them and promote their best interests.  
Lidz and Applebaum (2005) stated that patients recruited for research studies 
could not assume they had the same clinical goals and expected outcomes as the research 
investigators. The authors pointed out that the methods used in clinical research may 
significantly decrease clinical care. Lidz and Applebaum stated, “Patients come to the 
clinical research setting with expectations derived from both cultural images of the 
physician-patient relationship and their previous experiences with medical caregivers” 
(Lidz & Applebaum, 2005, p. 57). The authors acknowledged that while TM is widely 
recognized, little is known about affects in clinical research, including prevalence and 
consequences. Several studies have shown that the severity of illness affects retention of 
information and that the sickest patients were more likely to attribute therapeutic goals to 
research. Details regarding the study that researchers disclosed to participants have been 
identified in several previous studies as an important determinant of participants’ 
understanding in general (Lidz & Applebaum, 2005).  Lidz and Applebaum found that 
both the discussion between the investigator and the potential participant and the consent 
form should emphasize the difference between therapy and research. Specifically, 
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participants must be made aware that research is conducted to gain knowledge and not for 
therapeutic purposes (Lidz & Applebaum, 2005).    
Scott et al. (2009) conducted a pilot study of subjects enrolled in a Phase I test of 
gene transfer for Parkinson’s disease focusing on how the participants made their 
decision to participate. The primary goal of the pilot study was to understand how 
participants might fall into a misconception about the purpose of the research in which 
they have volunteered to participate. The approach of the study was to examine 
statements made by the participants that had potential implications for TM. They 
discovered that patients who volunteered for the gene study were highly motivated by a 
desire for therapeutic benefit. However, they also found that most participants with the 
desire for therapeutic benefit also understood the purpose of the study. Scott et al. found 
that there were many variations of the desire for therapeutic benefit and similar variations 
in the understanding of the purpose of the study. They found that most patient-
participants have “styles” of reconciling their motivations with their understanding that 
do not compromise understanding. Their data analysis revealed potential approaches for 
measuring and preventing TM. (Scott et al., 2009).   
Kass et al. (2009) reported that 17% of cancer patients enrolled in a Phase I 
cancer trial believed the trial offered a cure, 60% reported a purpose related to efficacy, 
and 17% related the study to dosing, safety, and side effects. The authors stated that if the 
reports regarding participants’ beliefs about clinical trials are based on a true 
misconception, this causes an ethical dilemma, especially for early phase trials where the 
primary purpose is to determine toxicity. Their work further documented that oncologists 
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usually provide potential participants with brief comments regarding the limited potential 
for treatment benefit linked with longer encouraging statements regarding research 
discoveries and breakthroughs. They concluded that regardless of the patients own 
outlook, ensuring that the differences among Phase I, II, and II trials are described and 
that risk/benefit information is clear is critical to the informed consent process (Kass et 
al., 2009).   
Prevalence 
Empirical studies of clinical trials, predominantly early stage cancer trials, 
indicated that participants were often motivated to participate in research by expectation 
of direct medical benefit, and when asked, blurred the distinction between research and 
treatment (Weinfurt et al. 2003). Weinfurt et al. (2003) noted that  
Research and treatment are often used as interchangeable terms, 
surrogate endpoints (e.g., tumor shrinkage, immune response) are 
discussed but not distinguished from clinical endpoints (e.g., survival 
time, improved quality of life) and that benefit to society and inclusion 
benefits are not distinguished from possible medical benefits for 
participants. (p. 167)   
Cohn, Jia, Smith, Erwin, and Larson (2008) conducted a pilot study testing the 
reliability and validity of an observational instrument measuring the process and quality 
of informed consent. The authors found that by direct observation of the informed 
consent process researchers were able to determine if patients suffering TM were not 
provided the information needed, did not remember or were confused regarding the 
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information provided or if the information was not explained in a language or manner 
that they could understand.  From this study, the investigators documented a number of 
issues in the informed consent process, including TM.  
Motivated by “genuine concern” for the welfare of cancer patients with advanced 
disease, Nurgat, et al. (2005) investigated the motivations and inhibitions of patients 
participating in cancer clinical trials, their understanding of the purpose of the research 
and alternative treatment options, and influences on their decision to participate in the 
clinical trial. Patients were surveyed after they had given informed consent and before or 
during the first cycle of treatment. Surveys were completed by 38 patients participating in 
Phase I and II cancer clinical trials: 89% listed obtaining possible health benefits as a 
very important factor in their decision to participate and only 17% listed helping future 
cancer patients as a very important factor in their decision to participate (Nurgat et al., 
2005). In this survey, most patients (97%) felt that they understood the purpose of the 
research and had given truly informed consent. Although Phase I and II cancer clinical 
trials seldom offer medical benefit, the authors found that most patients volunteered for 
trials based on a hope for medical benefit.  
In 2004, Barrett conducted a research study in order to describe clinical trials 
participants’ knowledge and understanding of the oncology clinical trial in which they 
were participating. Barrett used The Quality of Informed Consent (QuIC) questionnaire, 
developed by Joffe (2001), to assess the adequacy of informed consent.  This tool is a 
standardized measure for assessing informed consent in research and is based on the 
elements of informed consent specified in federal regulations (U.S. Department of Health 
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and Human Services, 2004). Barrett’s findings from this study, published in 2005, offered 
new insight into the problem of TM. Half of the sample failed to understand that clinical 
trial treatment is not standard treatment and may involve additional risk. Barrett 
concluded that although principle investigators (PIs) have the responsibility to ensure 
informed consent is obtained, clinical trials nurses do not communicate information 
adequately to obtain valid informed consent. The use of supplemental aids and resources 
may contribute to the nurse’s ability to communicate the information more adequately 
(Barrett, 2005). 
Therapeutic Misconception among Researchers 
 In a survey of oncologists, Joffe, Cook, Cleary, Clark, and Weeks (2001) 
concluded that clinical investigators hold different views on the purpose of conducting 
clinical research. The survey found that 20% of the participants believed that main 
purpose of clinical research was to provide patients with “state-of-the-art” therapy. This 
response may explain underlying tension about the moral justification of research: that 
subjecting patients to potentially risky research is unethical “unless clinical benefit is a 
legitimate research purpose” (p. 140). However, many bioethicists and clinical 
investigators find this opinion problematic because the purpose of research by nature is 
potentially risky and may involve consequences. These consequences may be because 
research and clinical care procedures and activities overlap or because administration of 
an experimental agent is seen both as a means to learn about the safety and 
efficacy and as an appropriate therapeutic option (Joffe et al., 2001). This debate reveals 
the difficulty of applying general assessments to trials that have very different study 
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designs. Instone, Mueller, and Gilbert (2008) noted that TM can occur within PIs and 
clinical trials nurses. While conducting a study of the informed consent process at their 
facility, they found that many of the documents and the language of the investigators and 
clinical trials nurses used the terms “treatment” and “treatment trial,” which suggested 
that the investigators and nurses believed the trial would offer the subjects some health 
benefit (Instone et al., 2008).  
 Few researchers who are also clinicians feel comfortable acknowledging, 
even to themselves, that an experimental course of treatment may not be optimally 
therapeutic for the patient (Applebaum & Roth, 1983). Even investigators who recognize 
the desirability of participants making informed decisions may have trouble conveying 
this particular information. Researchers should be encouraged to discuss such issues with 
participants and to include them on consent forms. Applebaum and Roth (1983) reported 
that participants' perceptions of the research team as willing to "level with them," even to 
the point of explaining why doing so might not be in participants' interests to participate 
in the study, may increase their trust and cooperation. Failure to address the TM during 
the consent process could increase distrust of researchers and the health care system in 
general, especially if subjects later believe they were "deceived” (Applebaum & Roth, 
1983).  
Review of Evidence 
Nursing Role in Research 
The rapidly growing field of clinical research offers a unique and challenging role 
for nurses. Clinical research nurses aid in the coordination, management, and conducting 
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of clinical research under the supervision of a designated investigator (Pick, Liu, Drew, & 
McCaul, 2010). Pick and colleagues stated that “The research nurse plays a key role as 
patient advocate, ensuring patient safety and protection and that the patients are well 
supported through out the research study” (Pick et al., 2010, p. 3). The Oncology Nursing 
Society (ONS) addressed the role of the oncology clinical research nurse in the Oncology 
Clinical Trials Nurse Competencies (2010) report. Ensuring patients give fully informed 
consent before being enrolled to trials is fundamental to the role (ONS, 2010). Making 
sure patients are given all of the information they need and that they fully understand the 
purpose of the study, including risks and benefits and that the choice to participate is 
completely voluntary are responsibilities of the research nurse (ONS, 2010).  
As the senior advisor for nursing for the Agency for Healthcare Research and 
Quality (AHRQ), Sharp, reported that while everyone’s role in healthcare is changing, 
one major focus of change that involves interdisciplinary collaboration is patient-
centered-care, which has always been a primary nursing value (AHRQ, 2012). The 
National Institute of Health Clinical Center delineates the responsibilities of the clinical 
research nurse by separating them into categories that include care coordination and 
continuity and human subject’s protection. These responsibilities include (a) providing 
nursing leadership within the interdisciplinary team, (b) providing nursing expertise to 
community-based health care personnel related to study participation, (c) facilitating the 
initial and ongoing informed consent process, (d) collaborating with the interdisciplinary 
team to address ethical conflicts, and (e) coordinating research activities to minimize 
subject risk (National Cancer Institute [NCI], n.d.).     
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Educating Nurses on TM  
 In response to the enactment of the Affordable Care Act (2010) the 
Institute of Medicine (IOM) released a report in 2011, “The Future of Nursing: Focus on 
Education.” This report explained that “the ways in which nurses were educated in the 
20th century are no longer adequate for dealing with the realities of health care in the 21st 
century” (IOM, 2011). As health care settings and patient needs continue to be 
increasingly complex, nurses must elevate their education and competencies in order to 
offer high-quality care; especially in the areas of research and evidence-based practice. 
Despite the increased number of nurses working in the field of research there remains two 
major obstacles to performing this role: lack of a clear, defined job description and lack 
of education and training to perform the responsibilities in this occupation (Spilsbury et 
al., 2008). Although educating and training new clinical research nurses are important, 
there is no standard requirement for training and education within the research industry 
(Bakker & Fitch, 1998). Individual facilities are responsible for setting their own 
standards for educating research nurses. As nurses are expected to have education, 
training and licensure to practice clinically, they should also be expected to have 
education and training to practice in the research arena (Spilsbury et al., 2008).      
Scott et al. (2013) indicated that The American Nurses Association ([ANA], 
2010) Standards of Practice can assist clinical trials nurses with prevention of therapeutic 
misconception. The authors concluded that based on the assumption that potential 
research subjects do not have all of the information needed to make a participation 
decision or there is a misunderstanding regarding the information they do have, a 
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diagnosis of knowledge deficit related to lack of information or misinterpretation of 
information, can be made. Scott et al. reported “If research subjects continue through the 
informed consent process with a knowledge deficit, a therapeutic misconception may 
result.” (p. 9). Research nurses must possess the ability to communicate clearly and give 
clear explanations. Clinical trial nurses should assess their ability to convey information 
and adjust their teaching approach to meet the patient’s and family’s teaching needs 
(Scott et al., 2013).  
Having well-trained, knowledgeable staff to administer a fully comprehensive 
consent process is essential (Pranati, 2010). Research nurses must be trained on human 
research participation protection and demonstrate respect and patience during the process. 
After providing all of the information, to complete the communication cycle, assessing 
how much the patient understands is important. This will enable the nurse to realize 
which areas are difficult for the participant to grasp and provide the opportunity to 
explain those elements more carefully to the next participants (Pranati, 2010).   
Ulrich stated that the knowledge and skills needed to care for patients 
participating in clinical trials is not included in most nursing school curricula (National 
Cancer Institute [NCI], 2012). She further states that the gap in nursing education can 
cause ethical difficulties. Ulrich (NCI, 2012) believes that every nurse should have a 
minimum of beginning-level competency in clinical research.     
Conceptual Model 
The term for the phenomenon currently known as “therapeutic misconception” 
originated with Applebaum et al. in 1982 after they observed psychiatric patients who 
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were obviously confused about research versus therapeutic treatment but consented to 
participate in research studies anyway. Matutina (2010) identified four elements present 
in TM in which patients/subjects 
• Confuse research with treatment. 
• Believe they will receive therapeutic benefit from research 
participation. 
• Fail to communicate “contribution to science” as motive for their 
participation in research. 
• Overestimate therapeutic response rates and misinterpret study 
purpose. 
Avant (2000), referring to the Wilson Method of Concept Analysis, stated that the 
social context in which a concept is found can provide valuable insight (see Appendix A 
for a concept map of TM). Matutina identified the social context of TM as research and 
believes the goals and motives of the researchers should be questioned. She stated that, in 
the very least, one should question whether or not researchers attempt to educate subjects 
regarding TM as they are recruited and whether or not, while obtaining informed consent, 
researchers stress the positives and downplay the negatives (Matutina, 2010).  
Gaps in Literature 
Although there has been considerable theoretical and empirical work on TM over 
the past thirty years, most of the work has focused on attempts to validate measures of 
TM or evaluate whether and to what degree TM invalidates the informed consent process. 
There are two obvious gaps in the literature referencing TM. There is a lack of literature 
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related to the development and implementation of a tool to measure TM. The “gold 
standard” for the measurement has historically been an open ended interview (Henderson, 
et al., 2007). An interview may determine the existence of TM but does not measure the 
magnitude of the condition. Also, while there is much literature to determine and validate 
the existence of TM there is very little knowledge and research attempting to decrease or 
alleviate the condition. In the current literature there is very little mention of the use of 
nursing interventions to decrease the existence of TM. 
Summary 
In the past decade deficiencies in the informed consent process have become a 
significant priority in the clinical research arena. Researchers worldwide are exploring 
ways and means to strengthen the process in terms of patient comprehension and 
autonomy and “must be careful in the language they use to describe their studies to avoid 
therapeutic misconception” (Steinke, 2004, p. 91). A genuinely knowledgeable and 
autonomous decision to participate in research is not only an ethical obligation but will 
ensure the participant remains involved through out the study (Pranati, 2014).  Glannon 
(2006) found that in many cases, the hope for direct benefit motivated people to 
participate in medical research. The author stated that even if clinicians and researchers 
carefully explained the difference between clinical care and research to patients and even 
if the consent process prominently stated that subjects were not likely to benefit from 
participation, the incidence of TM may be reduced but not eliminated.  Although 
obtaining informed consent may be a Principle Investigator’s (PIs) legal responsibility, 
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research nurses have an ethical responsibility to ensure patients’ understanding of the 








Section 3: Methodology 
Project Plan 
The clinical research nurse is often responsible for teaching and communicating 
specific details about a trial to the potential participant. Numerous opportunities to 
interact with research participants place the nurse in the position of being the one to 
discover the misconceptions regarding the purpose of the research study. Guiding patients 
through the consent process requires competent communication skills and specialized 
knowledge about human subjects’ protection (NCI, 2012). The research nurse must 
ensure that the patient understands that the purpose of the clinical trial is to gather 
scientific knowledge and that the subject may not benefit from participation.  
This project was accomplished by completing coordinated steps:  
1. A team of clinical trials experts was established. Team members were 
willing to participate in the creation of an educational program to be taught at their 
facility. Oncology nursing backgrounds were given preference.   
2. I led the project team in reviewing the relevant literature related to 
therapeutic misconception and nursing’s role in managing therapeutic misconception.   
3. The team developed an educational program for registered nurses. The 
educational program included concepts related to TM, guidance on recognizing TM 
in potential research subjects, strategies to correct potentials subject’s 
misunderstanding, and assessments of nurses’ understanding of related concepts and 
strategies.   
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4. The educational program was submitted to three scholars with expertise in 
nursing education and clinical trials for review and content validation. 
5. I led the project team in developing an implementation plan for the 
program. 
6. I led the project team in developing an evaluation plan for the program.  
Developing the Education Program  
The primary site of the project, Site A, was a small community healthcare 
organization in the coastal Southeastern section of the United States. The organization 
consists of two hospitals and two free standing community cancer centers. Clinical trials 
are offered through a partnership with an academic facility located 40 miles south of the 
primary site. Three other sites participated in the project and were chosen for the 
geographical location to the primary site, history of collaboration with the primary site, 
community setting, and participation in oncology clinical research. Site B was a 
community clinical oncology program that offers a center for cancer treatment and 
research and treats 1,300 newly diagnosed cancer patients annually. Site C was an 
academic facility with over 120 staff members employed in the research department that 
operates with 40 million dollars in funding. Site D offers a research center and cancer 
institute with over 70 oncology clinical trials currently open for accrual. Team members 
were chosen based on their expertise in oncology clinical trials, experience in the area of 
clinical research, and the varied training, knowledge and skills contributable to the team.  
Team members were chosen and responsibilities were delineated by the DNP student:   
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• As the project manager I (Site A) facilitated the activities of the team, 
organized meetings, and wrote the curriculum for the educational 
program.  
• A Radiation Oncologist (Site A) provided a principle investigator’s point 
of view during the development of the educational program.    
• Four research nurses, one from each of the participating sites, were the 
primary architects of the educational program.  
• The director of research for Site D assisted in the development of the 
educational program and in establishing the implementation plan.   
All of the participating facilities had access to web-conferencing technology. The 
team met via web-conferencing. A recurring meeting invitation was initiated by the 
project manager to the team members that once accepted appeared on their calendars. 
Team members were encouraged to share all information they determined to be relevant, 
including important aspects of TM.  A quality educational program was developed from 
the diverse backgrounds and individual expertise of team members.  Meetings were 
scheduled weekly for 5 consecutive weeks for the duration of 1 hour each. The first 
meeting focused on a review of the relevant literature related to TM and nursing’s role in 
managing TM. The second meeting established goals and a syllabus for the educational 
program. The third and fourth meetings were used to create the content (curriculum) of 
the program. Key aspects of the education program include the concepts of TM, methods 
to recognize TM, and strategies for correcting TM. The fifth meeting established the 
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duration of the educational program as five 1-hour classes as well as the design of the 
educational program using a classroom setting.  
The Walden University IRB reviewed the project plan and determined that the 
project met Walden University’s ethical standards. This Confirmation of Ethical 
Standards (CES) has an IRB record number of 12-26-14-0331603. No data were 
collected during the project.   
Resources and Budget 
Time was the most valuable as well as limited resource related to the completion 
of the project. Conflicting schedules proved to be a challenge in scheduling meetings 
with all team members in attendance. With today’s healthcare employees wearing 
multiple hats and working within limited budgets, there was limited time available for 
team members to engage in the many tasks associated with the project. There were no 
costs associated with this project, and no budget was required.  
Content Validation of Educational Program 
Once the program was developed, the curriculum was shared with all members of 
the team for final review and approval. The approved program was then shared with three 
experts in the field of nursing education and research for content validation.  One 
associate professor of nursing, one nursing instructor, and one director of clinical 
research (all registered nurses) examined the educational program content for validity.  
Developing the Implementation Plan 
 Following the completion of the project, each team member agreed to teach the 
program to the qualified nurses within their organizations. The director of research at Site 
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D has vast experience in implementing new programs within the healthcare arena 
(specifically research) and assisted in establishing the implementation plan for the 
educational program developed for this project.  
Developing the Evaluation Plan 
Following the completion of the project and my graduation, the educational 
program will be implemented and then evaluated. Outcomes will be measured for each of 
the objectives using a pre- and post-survey. As a part of the expected participation in the 
educational program, registered nurses will be asked to complete a survey designed to 
gauge their knowledge of TM. After participating in the educational program, the nurses 
will be asked to complete the same survey. Before and after comparisons will be made to 
evaluate whether or not the program positively affects the nurses’ knowledge of TM, 
their ability to recognize TM, and their confidence in their ability to correct participants’ 
misconceptions regarding the purpose of research. A pre- and post-test data collection 
tool offers “a measurement of the learning received during the [class] as a result of 
comparing what the student knew before in a pre-test and after in a post-test. The same 
instrument is used to collect data before and after the experience” (Diem, 2002, p. 1).   
Summary 
Nurses have important roles as advisors and potential referral sources for patients 
who are volunteering for clinical research. Investigators often consult with nurses about 
the appropriateness of particular patients as study participants. Therefore, nurses should 
receive education in the fundamentals of clinical trials design and process including 
consent and TM. It is expected that nurses will vary considerably regarding how much 
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time and effort they will spend helping their patients understand and consider 
participation in clinical trials. To advise patients optimally, it is desirable that all nurses 
appreciate the general aspects of how participation in a clinical trial differs from standard 
clinical practice (Steinke, 2004). These issues should be incorporated into the standard 
and continuing nursing education processes. As nursing and other health care 
professional students learn to interpret research literature in the practice of evidence-
based practice, how to advise patients concerning research participation could also be 
included in educational courses. The implications of clinical trials research are important 




Section 4: Findings, Discussion, and Implications 
Introduction 
Research and therapeutic clinical care involves different standards with regards to 
the treatment of the patient or research subject. The sole purpose of medical therapy is to 
treat an illness or injury and to improve health. The primary purpose of medical research 
is to gain knowledge. The confusion of the two often leads to profound 
misunderstandings on the part of the research subject. The purpose of this quality 
improvement project was to develop an educational program on therapeutic 
misconception for research RNs working in the oncology setting. The goal of the project 
was to improve RNs ability to decrease TM in clinical trials. This goal included several 
objectives to increase the RN’s (a) knowledge of therapeutic misconception, (b) skill in 
assessing subject’s misunderstanding of trials, and (c) ability to correct subject’s 
misunderstanding of the trial purpose. In achieving the objectives, the overall goal of the 
project was achieved.  
The outline for planning and designing the educational program (Appendix C: 
Educational Program on Therapeutic Misconception Syllabus) was adapted from Design 
for learning-A self paced guide by Cybela and Greer (1997). The implementation plan 
(Appendix D) was developed with the understanding that the educational program will be 
taught at several varying institutions. The program will be implemented by individual 
team members in a variety of organizational settings, allowing for slight adjustments to 
the implementation plan; however, the team has agreed that all team members will fully 
implement all aspects of the program. The evaluation plan (Appendix E) was created with 
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three time frames: short term, intermediate and long term evaluations. The Walden 
University Institutional Review Board (IRB) confirmed that this project meets Walden 
University’s ethical standards. This Confirmation of Ethical Standards (CES) has an IRB 
record number of 12-26-14-0331603.  
The Educational Program Syllabus 
Assessing the Need 
In order to manage time and cost, existing statistics and data were used to identify 
the need for educating research RNs regarding TM. Studies have found that some 
research participants do not understand important differences between research and 
treatment, a phenomenon called therapeutic misconception.  Research has shown that in 
Phase I oncology clinical trials, subjects generally do not understand the difference 
between the study purpose and cancer treatment. Nearly 90% of participants stated their 
goals in joining a Phase I study were the same as their goals in undergoing established 
cancer treatments (Daugherty, 2000).  Empirical studies of clinical trials, predominantly 
early stage cancer trials, indicated that subjects were often motivated to participate in 
research by expectation of direct medical benefit, and when asked, blurred the distinction 
between research and treatment (Weinfurt et al., 2003).     
The role of nursing in clinical research continues to expand, and research nurses 
must be aware of the concepts of TM and its impact on the consent process. The ONS 
addressed the role of the oncology clinical research nurse in the Oncology Clinical Trials 
Nurse Competencies (2010) report. Ensuring patients give fully informed consent before 
being enrolled to trials is fundamental to the role (ONS, 2010). Making sure patients are 
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given all of the information they need and that they fully understand the purpose of the 
study including risks and benefits and that the choice to participate is completely 
voluntary are responsibilities of the research nurse (ONS, 2010). Despite the increased 
number of nurses working in the field of research, there remains two major obstacles to 
performing this role: lack of a clear, defined job description and lack of education and 
training to perform the responsibilities in this occupation (Spilsbury et al., 2008). To date, 
there has not been a standard education program designed or implemented to educate the 
clinical trial nurse regarding TM.    
Plan and Design Team 
Team members were invited to participate in this project on a volunteer basis, 
without financial compensation, based on their clinical trials experience and expertise.  
Team members and responsibilities are as follows:   
• The project manager and I (Site A) facilitated the activities of the 
team, organized meetings, and wrote the syllabus for the 
educational program.  
• A Radiation Oncologist (Site A) provided a principle investigator’s 
point of view during the development of the educational program.    
• Four research nurses, one from each of the participating sites, were 
the primary architects of the educational program.  
• The director of research for Site D assisted in the development of 
the educational program and in establishing the implementation 
plan.   
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All of the participating facilities had access to web-conferencing technology. The 
team met via web-conferencing twice per week beginning on January 5, 2015 (Appendix 
B).  A recurring meeting invitation was initiated by the project manager to the team 
members and once accepted appeared on their calendars. Team members were 
encouraged to share all information they determined to be relevant including important 
aspects of TM.  An educational program was developed using the diverse backgrounds 
and individual expertise of team members as a resource.   
Target Audience 
The target audience for this educational program is registered nurses who care for 
the research subject in the adult oncology setting. Their motivation to learn is based on 
self-efficacy as well as quality of care for the research subject.  
Goals and Desired Outcomes 
The goal of the educational program is to improve RNs ability to decrease TM in 
clinical trials. This goal includes several objectives to increase the RN’s (a) knowledge of 
therapeutic misconception, (b) skill in assessing subject’s misunderstanding of trials, and 
(c) ability to correct subject’s misunderstanding of the trial purpose. In achieving the 
objectives, the overall goal of the project is achieved. Following the project completion, 
during the implementation and evaluation phases, the RN’s knowledge will be measured 
using a pre- and post-survey.  As a component of participation in the program registered 
nurses will be asked to complete a survey before and after the education program in order 
to gauge their knowledge of TM. Measures will include the RNs’ (a) knowledge of the 
existence and concepts of TM, (b) knowledge regarding the assessment of subject’s 
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understanding of trial, and (c) method of correcting the subjects misunderstanding of the 
trial purpose. 
Content/Subject Matter 
The first meeting was opened by me as a facilitator with an introduction to the 
purpose of the planning team and the purpose and expected outcome of the planning 
meetings. Each member of the team introduced themselves and gave a brief professional 
and educational history. This meeting focused on a review of the relevant literature 
related to TM and the nurses’ role in managing TM. In this first meeting, the team 
discussed the best way to approach an introduction to TM. The team decided that a brief 
literature review would be best, using the Appelbaum et al. (1982) article and the 
Henderson et al. (2007) article. The team agreed on the use of Henderson’s definition of 
TM. There was discussion regarding the increasing role of nurses in clinical trials and the 
importance of educating research nurses on the concepts of TM. A decision was made 
that the information from ONS (2010) on informed consent and the research of Matutina 
(2010) would be useful in presenting the role of the research nurse to the participants of 
this program. Information from Judkins-Cohn et al. (2014) will be included in the 
instruction on the principles of informed consent and the research nurse’s role.  
The second meeting established goals and discussed content for the educational 
program. In the second meeting, the team discussed the goals of the program, how they 
would be achieved, and in what order the information would be presented. The team 
established that the learning should be engaging and enjoyable. Content should be 
presented in a manner that allows learners to build upon the previous content. The team 
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began to establish the syllabus and time requirements for each of the covered topics. 
There was discussion of a format with an agreement to reevaluate this time frame and 
format at the fifth and final meeting. The team agreed that a Power Point presentation 
should be created in order to assist instructors with staying on task and within allotted 
time frame.  A hard copy of the presentation will be made available to each of the 
participants with space available for taking notes.  
The third and fourth meetings were used to create the content of the program. Key 
aspects of the education program include the concepts of TM, methods to recognize TM, 
and strategies for correcting TM. In the third meeting, the team discussed the history of 
the consent process. The team agreed that a brief review of the Belmont report and the 
Nuremburg Trials would be appropriate and that there should be a presentation on the 
impact of TM on the consent process. There was a review of information regarding 
strategies for recognizing TM in patients and family members and strategies to correct 
misunderstanding of research purpose. The team decided that the information provided 
by Meropol et al. (2003) would be appropriate for use in teaching this topic. There was 
discussion on why the QuIC (Joffe et al., 2001) was not sufficient, that determining the 
presence of TM does nothing to alleviate or decrease the condition and that this should be 
shared with participants.  
In the fourth meeting, there was discussion on teaching methods of potential 
subjects and families designed to alleviate TM. There was discussion on the need to teach 
peers and physicians regarding TM and sharing suggestions to decrease TM. The team 
agreed that the information from deMelo-Martin and Ho (2008) as well as Glannon 
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(2006) would be used for teaching this topic. Further development of the syllabus was 
achieved.  
The fifth meeting established the duration of the educational program as well as 
the design of the educational program. In the fifth and final meeting, the content and 
syllabus was completed. The team agreed five 1-hour sessions was sufficient and a 
classroom format was appropriate. The classroom format was chosen to ensure learner 
interaction and because of the severe consequence if learners were unable to adequately 
perform tasks. The team established that the program should be offered to groups no 
larger than 12 to a class to ensure active participation from the attendees. Members 
shared ideas for teaching the program in their respective facilities. There was brief 
discussion regarding the inclusion of staff development within the organizations and 
applications for continuing nursing education credits from nursing boards of each state.   
The curriculum was shared with all members of the team for final review and 
approval. All team members concurred that the presentation and syllabus reflected what 
the team had agreed on. Following the content validation review each team member was 
contacted via e-mail regarding content validation results.   
Content Validation 
The educational program content and curriculum was shared with three experts in 
the field of nursing education and research for content validation.  One associate 
professor of nursing, one nursing instructor, and one director of clinical research (all 
registered nurses) examined the educational program content for validity (Appendix C 




The educational program will be presented in a classroom format. Materials 
include scholarly articles for discussion that are available via the internet and brief 
lectures.  
Budget 
The cost of the program includes time and materials. Materials include scholarly 
articles for discussion that are available via the Internet. The greatest expense will be 
incurred in wages for the RNs participating in the educational program. According to the 
Bureau of Labor Statistics (2013), the medium wage for a research nurse is $35.00 per 
hour. The program is designed to be 5 hours long. Each participating location has an 
average of 12 research nurses. The cost for RN wages per location is estimated to be 
$2,100.00. Each organization will be responsible for the wages of their RNs. The six 
team members responsible for teaching the program are all salaried employees and have 
agreed to work the additional hours required for the program.       
Implementation Plan 
Following the completion of the project and my graduation, the educational 
program will be implemented (Appendix D). Each member of the development team has 
agreed to teach the program to the qualified nurses within their organization. Team 
members will be responsible for identifying qualified participants and securing 
appropriate space for the classes. It is expected that the research RN will acquire useful 
knowledge and skills and use them in practice, changing practice in the research 
department. Therefore, senior leaders and key stakeholders must be instructed about and 
40 
 
endorse the educational program in order to secure successful outcomes. There should be 
consideration and agreement on compensation of the RNs time commitment for the 
program, whether this will be financial compensation or take another form. The 
scheduling of the program is left up to the team member; however, the five classes should 
be scheduled no longer than 1 week apart.   
Evaluation Plan 
Following the completion of the project and my graduation, the educational 
program will be evaluated (Appendix E). Both short term and intermediate term 
outcomes will be measured for each of the objectives using a pre- and post-survey. Prior 
to participation in the educational program, registered nurses will be asked to complete a 
survey designed to gauge their knowledge of TM. After participating in the educational 
program, the nurses will be asked to complete the same survey. Before and after 
comparisons will be made to evaluate whether or not the education positively affects the 
nurses’ knowledge of TM, their ability to recognize TM, and their confidence in their 
ability to correct subjects’ misconceptions regarding the purpose of research. A test run 
of data entry and analysis will be performed to reduce the likelihood of unwanted 
surprises or wasted data. A track bar numbered 0-8 will be used to represent continuous 
data with a higher score corresponding to a higher level of knowledge. The main 
independent variable will be pre-versus-post-TM knowledge. Internal reliability will be 
evaluated using Cronbach’s alpha. Data analysis will be performed using a paired sample 
student’s t-test. The results of a t-test will reveal whether or not the difference between 
the pre and post survey is significant. The short term threshold for success will be 
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reached at significance levels less than .05. Results will be used to make decisions 
regarding the modification of the educational program. 
The long term evaluation plan will be my sole responsibility. The long term goal 
for educating research RNs on TM is to decrease the incidence of TM among research 
subjects. Therefore, the long term evaluation of the educational program is designed as a 
study to measure TM among research subjects before and after the educational program 
is taught to participating research RNs.  
During the five weeks that the educational program is being taught to research 
RNs, patients recently enrolled in clinical trials at Sites A, C, and D will be surveyed 
using the Quality of Informed Consent (QuIC) questionnaire (Appendix F) (Joffe et al., 
2001).  Twelve months later this process will be repeated at sites A, C, and D and within 
each institution, comparisons made using before education and after education data. Data 
comparisons will be made to assess the long term outcomes of the educational program 
and to determine whether or not there is decreased incidence of TM among the subjects 
enrolled in clinical trials. Success of the educational program will be determined by a 
lower incidence of TM among research subjects after education of the research RNs as 
compared to incidence of TM among research subjects before education of the research 
RNs.  
Quality of Informed Consent Questionnaire 
The QuIC is a standardized measure of assessing the quality of understanding 
among participants in clinical trials. The QuIC questionnaire is based on 13 independent 
domains derived from the eight basic elements of informed consent specified in federal 
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regulations. The questionnaire is written at an eighth-grade reading level and requires an 
estimated seven minutes to complete. The QuIC consists of three parts. Part A contains 
20 questions and measures subject’s knowledge of the basic elements of informed 
consent. Part B contains 14 questions and measures the understanding of the important 
elements of the specific trial in which subjects consented to participate. Part C covers 
subject’s perception of the informed consent process, demographic characteristics, and 
previous participation in research. Content validity of the questionnaire was established 
after review by two independent panels of experts in the fields of bioethics, statistics, 
oncology, and clinical trial design (Joffe et al., 2001). Test re-test reliability was 
examined with intraclass correlation coefficients of 0.66 for tests of objective 
understanding and 0.77 for tests of subjective understanding (Joffe et al., 2001).   
Project Completion 
The most difficult portion of the development of the educational program was 
organizing the process. The written plan helped to make the organization slightly less 
difficult. Research staff from the varying organizations was pleasantly easy to work with 
and enthusiastic about the project however, scheduling was an issue. We managed to 
complete our development meetings with most of the team members in attendance at 
each meeting.  Organizing, implementing, and evaluating new services in healthcare was 
not a new concept to this student however the educational piece was a new endeavor. 
With very little experience in teaching the knowledge and teaching background of several 
team members was invaluable.  
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Implications for Future Research 
Research on TM has been motivated by concern that participants may 
misunderstand aspects of trial care that lead them to make decisions incompatible with 
their true preferences and values. Refining the standard education of TM for registered 
nurses can serve both to improve the protection of trial participants and clarify the 
informed consent process. Though participants may recognize they are in a trial, failure 
to understand how care received during a trial can differ from standard care, and 
confusion over the purpose of these distinct activities, can compromise informed consent 
to research participation. Progress can be made in alleviating TM by focusing on the 
aspects of informed consent that clearly interfere with trial participants' decision-making 
through failure to understand the defining nature and purpose of clinical research 
(Barrett, 2005). Future research efforts need to focus on the development of nursing 
interventions that improve the informed consent process as well as enhance patients’ 
understanding of the research process. With education and understanding regarding TM, 
nurse researchers may play a key role in preventing this condition (Matutina, 2010).   
Strengths and Limitations  
The educational project was developed by a team of experts in the field of 
research nursing. It was validated by a team of experts in nursing education and research. 
A strong implementation plan has been developed with the ability to adjust the 
educational program as needed based on the evaluation. The evaluation plan is well 
developed and designed for both short and long term success.  
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This project was limited by the varied geographical locations of the team 
members, the dependence on technology, and the variance of multiple schedules. The 
team consisted of clinical trials experts employed at several facilities through-out the 
state. Communication among the team members was accomplished via e-mail and 
meetings were conducted using telephone conference lines. Conflicting schedules proved 
to be a challenge in scheduling meetings with all team members in attendance. 
Self-Analysis  
One of the greatest challenges I face today is learning to be an effective leader. I 
believe an effective leader possess both education and experience. My desire to learn and 
better myself in order to increase my leadership skills led me to pursue a DNP.  With the 
completion of this degree and project I have increased both my education and experience. 
The amount of energy and dedication required to complete this doctoral program was 
tremendous. The fact that I am so close to accomplishing this goal tells me that I remain 
dedicated and committed to success in both my career and life goals. I may very well 
have what it takes to be successful in a leadership role within healthcare and nursing.    
Summary 
TM may be decreased or alleviated by educating nurses involved in research on 
the existence and concepts of TM, allowing subjects a much clearer picture of the relative 
risks and benefits of participation in a clinical trial. Diligent examination of potential 
research subjects should expose truly altruistic reasons for participating in the trial. 
Potential subjects should understand and accept that they may not benefit medically from 
participation in a clinical trial. Individual facilities are responsible for setting their own 
45 
 
standards for educating research nurses. As evidenced by research presented in this 
project, there is no standard education for research nurses regarding TM. It is the hope of 
the author that this project will change this situation and facilities will include TM in the 




Section 5: Scholarly Product 
An Educational Program for Nurses on Therapeutic Misconception in the Oncology Setting 
Abstract 
A key component of informed consent to participate in research is the 
understanding that research is not the same as treatment, that scientific goals have priority 
over therapeutic ones. However, studies have found that some research participants do 
not understand important differences between research and treatment, a phenomenon 
called therapeutic misconception (TM). An important element when recruiting for 
clinical trials is to ensure the potential subject understands that therapeutic benefit to the 
individual is secondary to the overriding goal of the research study. The role of nursing in 
clinical research continues to expand and research nurses must be aware of the concepts 
of TM and its impact on the consent process. The problem addressed in this project was 
the research nurse’s education regarding the existence and concepts of TM and the ability 
to assess and correct if necessary, the research subject’s understanding of the trial. To 
date there has not been a standard education program designed or implemented to educate 
the clinical trial nurse regarding TM.  The purpose of the project was for an established 
team of clinical trials experts to develop an educational program for registered nurses on 
TM that enables them to assess clinical trials patients for the influence of TM and correct 
any misunderstanding the subject may have regarding the benefits and purpose of 
participation in the clinical trial. The educational program included concepts related to 
TM, guidance on recognizing TM in potential research subjects, and strategies to correct 




Studies have found that some research participants do not understand important 
differences between research and treatment, a phenomenon called therapeutic 
misconception (TM). TM arises from the conviction that the purpose of clinical medicine 
and clinical research is to benefit the patient, and that a physician will always act 
according to what is the best medical care for the patient (Applebaum, Anatchkova, 
Albert, Dunn, & Lidz, 2012). When recruiting for clinical trials, healthcare providers 
must ensure potential subjects understand that therapeutic benefit to the individual is 
secondary to the overriding goal of the research study. A key component of informed 
consent to participate in research is the understanding that research is not the same as 
treatment. Ethicists contend that informed consent to participate in research should 
explain the difference between research and treatment in language that the lay person will 
understand (Applebaum, Roth, & Lidz, 1982). Applebaum, Roth, & Lidz (1982) original 
study found that many of the study participants believed they were receiving treatment in 
the form of a medication, based on what was most therapeutic to them personally, despite 
being told by the researchers that they were participating in a clinical trial in order to 
discover scientific knowledge, and that they may not benefit from participation in the 
trial. Barrett (2005) states that “although participants are explicitly told that scientific 
goals have priority over therapeutic ones and investigators’ primary interests are in 
improving treatment options, participants persist in believing that they will receive 
benefit from their involvement in the research” (p. 752).  
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The Nuremburg Code clearly states that research participation be undertaken 
“without the intervention of any element of force, fraud, deceit, duress, over-reaching, or 
other ulterior form of constraint or coercion…” (International Military Tribunal, 1949). 
Black, Batist, Avard, Rousseau, Diaz, and Knoppers (2013), citing the World Medical 
Association (1964), state that “the requirement of voluntariness has been confirmed 
universally over the years as an essential element of research participation” (p. 26). The 
misunderstanding of the purpose of research (TM) has the potential to compromise the 
voluntariness of consent by creating a risk-benefit perception by the patient that does not 
coincide with the reality of the trial. “As patient advocates and educators, nurses must be 
able to assess individuals’ understanding to ensure the validity of the informed consent 
process” (Barrett, 2005, p.752).  
Problem  
TM is a critical problem in research clinical trials (Applebaum et al., 2012). 
Research and therapeutic clinical care involves different standards with regards to the 
treatment of the patient or research subject. The sole purpose of medical therapy is to 
treat an illness or injury and to improve health. The primary purpose of medical research 
is to gain knowledge. The confusion of the two often leads to profound 
misunderstandings on the part of the research subject. The role of nursing in clinical 
research continues to expand and “nurses must develop strategies that provide clinical 
trial patients with a better understanding of the trial they are considering, identify areas of 
misunderstanding and correct them, and assess the outcomes of the informed consent 
process” (Barrett, 2005, p. 752). This project addressed the problem of the research 
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nurse’s education regarding the existence and concepts of TM and the ability to assess 
and correct if necessary, the research subject’s understanding of the trial. The problem 
addressed in the project was the lack of knowledge among registered nurses regarding 
TM.  
Purpose  
Historically, research on TM has been conducted because of concern that 
participants may misunderstand aspects of trial care that lead them to make decisions 
incompatible with their true preferences and values. Obtaining informed consent, 
permission granted by patients for healthcare services, knowing the possible 
consequences, is an ethical obligation of nurses and other health care providers. 
Registered nurses working with clinical trial subjects should (a) understand the concepts 
of TM as well as the potential negative impact on the informed consent process, (b) be 
able to assess clinical trials patients for the influence of TM, and (c) be able to correct 
any misunderstanding the subject may have regarding the benefits and purpose of 
participation in the clinical trial. The purpose of the project was to develop an educational 
program for registered nurses (RNs) on TM.  
Goals and Outcomes 
The goal of the project was to improve RNs ability to decrease TM in clinical 
trials. This goal included several objectives to increase the RN’s (a) knowledge of 
therapeutic misconception, (b) skill in assessing subject’s understanding of trials, and (c) 
ability to correct subject’s misunderstanding of the trial purpose.  In achieving the 
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objectives, the overall goal of the project was achieved. The objectives were measured in 
the evaluation phase using a pre and post survey.   
As a component of participation in the program registered nurses were asked to 
complete a survey before and after the education program in order to gauge their 
knowledge of TM. Measures included the RNs’ (a) knowledge of the existence and 
concepts of TM, (b) knowledge regarding the assessment of subject’s understanding of 
trial, and (c) method of correcting the subjects misunderstanding of the trial purpose.  
Significance for Future Practice 
Judkins-Cohn, Kielwasser-Withrow, Owen, and Ward (2013) state that during the 
past twenty years there has been an increase in developing policies that ensure the use of 
research and evidence-based practice for both nursing and medicine in the clinical 
setting. With the increase in research activities, more nurses are engaging in research as 
Principle Investigators (PIs) and members of research teams. The 2010 Institute of 
Medicine’s Future of Nursing report recommended that by 2020 there will be a need for 
double the current number of doctoral prepared nurses. “The result is the creation of the 
dual role of care provider and researcher” (Judkins-Cohn et al, 2013, p 4199).  This dual 
nursing role demands a thorough understanding of the informed consent process. This 
understanding includes the difference between the goals of clinical care and research 
(TM), following research-specific ethics involved in the informed consent process, and 
understanding quality measures of the informed consent process. 
The TM is a serious problem for informed consent in clinical research and 
conflicting desired health outcomes for healthcare providers and patients suggest 
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implications for nursing practice. Applebaum and Roth (1983) raise the question, “Who 
should have the task of explaining the therapeutic misconception to subjects?” (p.12). 
Institutional policies typically require that potential subjects be approached about 
research by someone known to them, and that the consent process must be conducted by 
someone who fully understands the research study. The PI for a research study may also 
be the healthcare professional caring for a potential research subject.  
The PI may be the person most knowledgeable about the research and most 
qualified to approach the potential subject, however, they may not be the best person to 
complete the informed consent process. Because of the potential for TM, there may be 
benefit to having a research study team member that is not the PI involved in the consent 
process (Pranati, 2010). The PI has a responsibility to distinguish between treatment and 
research, and to clearly explain the implications for the potential subject.  However, even 
when a PI clearly emphasizes that the goal of the research is not to provide care, patients 
sometimes continue to believe that the research will provide them with direct benefit 
(Pranati, 2010). Pranati also states that a solution to this challenging situation is to have 
the research nurse complete the informed consent process after the PI has explained the 
research in detail. The study nurse can then determine whether the patient understands the 
research and his/her willingness to participate outside the direct influence of the PI. 
Clinical trial nurses must communicate information about the nature and goals of clinical 
research, explain the details of the specific study, and assess subjects’ understanding of 




The societal response to ethical problems associated with clinical research has 
been the implementation of regulatory laws and policies, including detailed federal 
regulations governing research involving human subjects (Miller, Rosenstein, & 
DeRenzo, 1998). The application of these regulations has led to improved protection of 
the rights and welfare of research subjects; however, there remain deficiencies that need 
to be addressed (Miller, Rosenstein, & DeRenzo, 1998). Changes to consent procedures 
should be adopted to ensure that all potential subjects are aware that their condition and 
benefit is not the priority of the clinical trial (Pranati, 2010). Diligent examination of 
potential research subjects should expose truly altruistic reasons for participating in the 
trial. Potential subjects should understand and accept that they may not benefit medically 
from participation in a clinical trial.  
Evidence 
Solid understanding of research ethics requires the clear distinction between 
research and therapeutic treatment. The first principle of The Belmont Report (1979), 
which is the ethical basis for the U.S. federal regulations, is “respect for persons”—
persons have the right to decide for themselves whether to participate in research on the 
basis of information provided about the nature of the trial, potential benefits and adverse 
effects, alternative treatments, etc. In order to decrease the incidence of TM, researchers 
must be judicious in their use of the term “treatment” (Banks, 2009). When a study drug, 
study intervention, or investigational therapy is referred to as a treatment there is an 
increased chance that a potential subject will misinterpret the purpose of the trial. The 
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patient-subject who thinks they are receiving individualized therapy when in fact they are 
being treated according to a research protocol cannot give informed consent (Steinke, 
2004).      
Kola and Landis (2004) reported that the average success rate for new drugs was 
11%, ranging from 20% in cardiovascular trials to 5% in oncology trials. They found that 
60% of the time, the reasons that the drugs did not make it to market were efficacy and 
safety. It is very likely, in oncology phase I and II trials that the patient will not benefit 
and consent language must state this clearly (Kola & Landis, 2004). The mere disclosure 
of risks and benefits in lengthy and legalistic forms may not be sufficient in light of such 
evidence (Barrett, 2005). Evidence suggests transforming the informed consent process 
from passive disclosure to more active education and interaction with patient participants 
in clinical research (Pranati, 2010). When discussing a subject’s expectations of direct 
benefit, only the benefits that can be “reasonably expected” should be discussed (Banks, 
2009). This clarification will help subjects understand the potential benefits of the 
research, as well as the alternatives to the research that are available. 
Conceptual Model 
The term for the phenomenon currently known as “therapeutic misconception” 
originated with Applebaum et al in 1982 after they observed psychiatric patients who 
were obviously confused about research versus therapeutic treatment but consented to 
participate in research studies anyway. Matutina (2010) identified four elements present 
in TM in which patients/subjects 1) confuse research with treatment, 2) believe they will 
receive therapeutic benefit from research participation, 3) fail to communicate 
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“contribution to science” as motive for their participation in research, and 4) overestimate 
therapeutic response rates and misinterpret study purpose.  
Avant (2000), referring to the Wilson Method of Concept Analysis, stated that the 
social context in which a concept is found can provide valuable insight (see Appendix A 
for a concept map of TM). Matutina identified the social context of TM as research and 
believes the goals and motives of the researchers should be questioned. She stated that, in 
the very least, one should question whether or not researchers attempt to educate subjects 
regarding TM as they are recruited and whether or not, while obtaining informed consent, 
researchers stress the positives and downplay the negatives (Matutina, (2010).  
Approach 
This project was accomplished by completing the following steps:  
1. A team of clinical trials experts was established. Team members were willing 
to participate in the creation of an educational program to be taught at their facility. 
Oncology nursing backgrounds were given preference. Team members were invited to 
participate in this project on a volunteer basis, without financial compensation, based on 
their clinical trials experience and expertise. The project manager and DNP student (site 
A) facilitated the activities of the team, organized meetings, and wrote the syllabus for 
the educational program. A Radiation Oncologist (site A) provided a principle 
investigator’s point of view during the development of the educational program. Four 
research nurses, one from each of the participating sites, were the primary architects of 
the educational program. The director of research for site D assisted in the development 
of the educational program and in establishing the implementation plan.   
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2. All of the participating facilities had access to web-conferencing technology. 
The team met via web-conferencing twice per week beginning on January 5, 2015 
(Appendix B).  A recurring meeting invitation was initiated by the project manager to the 
team members and once accepted, appeared on their calendars. Team members were 
encouraged to share all information they determined to be relevant including important 
aspects of TM.  An educational program was developed using the diverse backgrounds 
and individual expertise of team members as a resource.   
3. The DNP student led the project team in reviewing the relevant literature 
related to therapeutic misconception and nursing’s role in managing therapeutic 
misconception.   
4. The team developed an educational program for registered nurses. The 
educational program included concepts related to TM, guidance on recognizing TM in 
potential research subjects, strategies to correct potentials subject’s misunderstanding, 
and assessments of nurses’ understanding of related concepts and strategies. The outline 
for planning and designing the educational program (Appendix C: Educational Program 
on Therapeutic Misconception Syllabus) was adapted from Design for Learning-a self 
paced guide by Cybela & Greer (1997). 
5. The educational program was submitted to three scholars with expertise in 
nursing education and clinical trials for review and content validation. 
6. The DNP student led the project team in developing an implementation plan 
for the program. The implementation plan (Appendix D) was developed with the 
understanding that the educational program will be taught at several varying institutions. 
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The program will be implemented by individual team members in a variety of 
organizational settings allowing for slight adjustments to the implementation plan 
however, the team has agreed that all team members will fully implement all aspects of 
the program. 
7. The DNP student led the project team in developing an evaluation plan for the 
program. The evaluation plan (Appendix E) was created with three time frames; short 
term, intermediate, and long term evaluations. 
Implementation Plan 
Each member of the development team has agreed to teach the program to the 
qualified nurses within their organization. Team members will be responsible for 
identifying qualified participants and securing appropriate space for the classes. It is 
expected that the research RN will acquire useful knowledge and skills and use them in 
practice; changing practice in the research department. Therefore senior leaders and key 
stakeholders must be instructed about and endorse the educational program in order to 
secure successful outcomes. There should be consideration and agreement on 
compensation of the RNs time commitment for the program; whether this will be 
financial compensation or take another form. The scheduling of the program is left up to 
the team member however the five classes should be scheduled no longer than one week 
apart.   
Evaluation Plan 
Both short term and intermediate term outcomes will be measured for each of the 
objectives using a pre and post survey. Prior to participation in the educational program, 
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registered nurses will be asked to complete a survey designed to gauge their knowledge 
of TM. After participating in the educational program, the nurses will be asked to 
complete the same survey. Before and after comparisons will be made to evaluate 
whether or not the education positively affects the nurses’ knowledge of TM, their ability 
to recognize TM, and their confidence in their ability to correct subjects’ misconceptions 
regarding the purpose of research. A test run of data entry and analysis will be performed 
to reduce the likelihood of unwanted surprises or wasted data. A track bar numbered 0-8 
will be used to represent continuous data with a higher score corresponding to a higher 
level of knowledge. The main independent variable will be pre-versus-post-TM 
knowledge. Internal reliability will be evaluated using Cronbach’s alpha. Data analysis 
will be performed using a paired sample student’s t-test. The results of a t-test will tell us 
if the difference between the pre and post survey is significant. The short term threshold 
for success will be reached at significance levels less than .05. Results will be used to 
make decisions regarding the modification of the educational program. 
The long term evaluation plan will be the sole responsibility of the DNP graduate. 
The long term goal for educating research RNs on TM is to decrease the incidence of TM 
among research subjects. Therefore, the long term evaluation of the educational program 
is designed as a study to measure TM among research subjects before and after the 
educational program is taught to participating research RNs.  
During the five weeks that the educational program is being taught to research RNs, 
patients recently enrolled in clinical trials at Sites A, C, and D will be surveyed using the 
Quality of Informed Consent (QuIC) questionnaire (Appendix F) (Joffe et al., 2001).  
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Twelve months later this process will be repeated at sites A, C, and D and, within each 
institution, comparisons made using before education and after education data. Data 
comparisons will be made to assess the long term outcomes of the educational program 
and to determine whether or not there is decreased incidence of TM among the subjects 
enrolled in clinical trials. Success of the educational program will be determined by a 
lower incidence of TM among research subjects after education of the research RNs as 
compared to incidence of TM among research subjects before education of the research 
RNs. 
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Appendix A: Conceptual Map of Therapeutic Misconception 
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Appendix B: Meeting Agendas 










From:  4:00p.m.     To:  5:00p.m. 
 
Dial-in-Number 
1 (646) 558-2119 
 
Pass code 












Participants Brief introductions Group  
Literature Review of TM Articles previously provided-discussion on findings Group  



















From:  4:00p.m.     To:  5:00p.m. 
 
Dial-in-Number 
1 (646) 558-2119 
 
Pass code 












Goals of Program Discussion, Establish and document Group  














From:  4:00p.m.     To:  5:00p.m. 
 
Dial-in-Number 
1 (646) 558-2119 
 
Pass code 












Syllabus/Content Discussion, Establish, document Group  
Informed Consent History, TM’s impact on Group  
 
 










From:  4:00p.m.     To:  5:00p.m. 
 
Dial-in-Number 
1 (646) 558-2119 
 
Pass code 












Content/Syllabus Discussion, Establish, document Group  















From:  4:00p.m.     To:  5:00p.m. 
 
Dial-in-Number 
1 (646) 558-2119 
 
Pass code 












Duration and Format Discussion, establish, document Group  
Wrap Up Suggestions and feedback, thank you Group  













Appendix C Educational Program Syllabus 
Educational Program on Therapeutic Misconception Syllabus 
Instructor and Organization TBD 
Location and time TBD 
Description 
This five week educational program was designed to enhance nurse success in 
recognizing and decreasing therapeutic misconception (TM). In this program you will be 
offered strategies for teaching patients and family members without introducing TM, 
guidance in recognizing TM in potential research subjects and strategies to correct 
potentials subject’s misunderstanding. In addition, we will explore your knowledge and 
skills in understanding related concepts and assessing subjects for TM.  
Learning Objectives 
1. You will increase your knowledge of TM and it’s concepts allowing you to teach 
trial subjects without introducing TM 
2. You will increase your skill in assessing subjects understanding of the clinical 
trial they are considering 
3. You will increase your ability to correct subject’s misunderstanding of the 
purpose of the clinical trial 
Participation 
 
As a component of participation in the program you will be asked to complete a survey 
prior to beginning the program and immediately after completing the program. This is an 
interactive program; questions and energetic participation are welcome through-out. 
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Students may vary in their learning. Obtaining competencies and achieving program 
goals requires work on the student’s part. Absences should be discussed with the 
instructor; it will be the responsibility of the student to complete reading and other 
assignments that they miss. At the discretion of the instructor-more than one absence will 
likely require the student to repeat the program. Respect and courtesy for fellow students 
is required, the personal use of cell phones and tablets should not occur while classes are 
in progress.  
Schedule  
 
Week One: Introduction to TM 
 
Instructor Introduction 
• Educational and professional background 
• Contact information and availability 
• Institutional or departmental policies: CMEs, disabilities, diversity  
Pre Survey Completion 
• To be completed by each student-electronically (i.e. Survey Monkey) 
Purpose and Objectives Review 
• Review of program objectives and expected learning outcomes 
• Review of major topics of the program 
• Program information 
• How the program relates to clinical trials and nursing 
• Electronic access to articles and resources-hard copies provided in class 
Introduction to TM 
• “Discovery” and Concepts  
• Operational definition 
Reading Materials 
Appelbaum, P., Roth, L. & Lidz, C. (1982). The therapeutic misconception: Informed 
consent in psychiatric research. International Journal of Psychiatry, 5, 319–329. 
 
Lidz, C.W. & Applebaum, P.S. (2002). The therapeutic misconception: Problems and 
solutions. Medical Care, 40(9), 55-63. doi: 10.1097/01.MLR.0000023956.25813.18 
  
Matutina, R.E., (2010). The concept analysis of therapeutic misconception. Nurse 




Henderson, G.E., Churchill, L.R., Davis, A.M., Easter, M.M., Grady, C., Joffe, S.,… 
Zimmer, C.R. (2007). Clinical trials and medical care: defining the therapeutic 
misconception. Plos Medicine, 4(11), 1735-1738. doi: 10.1371/journal.pmed.0040324  
Retrieved from 
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0 
040324     
 
Truong, T.H., Weeks, J.C., Cook, E.F., Joffe, S. (2011). Altruism among participants in 
cancer clinical trials. Clinical Trials, 8, 616-623. doi: 10.1177/174077451141444 
  
Week Two: Nursing Role and Teaching 
 
Increased role of nursing in clinical trials 
• History of clinical research nursing 
• Role description and evaluation-pivotal and complex  
• Increased emphasis on clinical research 
• Structure, function and management of research-fluid 
• Contributions and obligations of research nurse 
Importance of research RN’s understanding of TM 
• Scientific and Ethical Integrity  
• Motives and welfare of individual patients 
• Prevention, Recognition, Correcting Misunderstanding 
Strategies for teaching patients and families 
• Examine your own views-potential to influence subject’s opinions 
• Avoid mixed messages, use clear explanation, care with use of terms (treatment 
and therapy) 
• Interview patient regarding desired goals and expectations 
• Potential benefits, potential harms, right to withdraw 
• Tools and mixed methods of providing information 
Reading Materials 
Agency for Healthcare Research and Quality (2012). The changing role of nurses. 
Retrieved from http://www.ahrq.gov/news/newsletter/research-         
activities/12dec/1212RA1.html  
 
Gibbs, C.L. & Lowton, K. (2012). The role of the clinical research nurse. Nursing 
Standard, 26, 37-40. Retrieved from: www.nursing-standard.co.uk  
 
Ocker, B.M. & Pawlik, D.P. (2000). The research nurse role in a clinic-based oncology 
research setting. Cancer Nursing, 23(4), 286-292. Retrieved from: 
http://ovidsp.tx.ovid.com.ezp.waldenulibrary.org/sp-3.13.1a/ovidweb.cgi  
 
Spilsbury, K., Petherick, E., Cullum, N., Nelson, A., Nixon, J., Mason, S. (2008). The 
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role and potential contribution of clinical research nurses to clinical trials. Journal of 
Clinical Nursing, 17(4), 549-557. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/17419791  
 
National Cancer Institute (2012). A balancing act: nursing and ethics in clinical trials. 
NCI Cancer Bulletin, 9(15). Retrieved from:  
http://www.cancer.gov/ncicancerbulletin/072412  
 
Week Three: Informed Consent and TM 
 
History of Informed consent 
• The Belmont Report 
• Ethical principles 
• Fully informed and voluntary  
• Transparent, language that is understandable 
• Written and verbal-complete disclosure 
TM’s potential impact on consent 
• Autonomy, beneficence, and justice 
• Dual role-provider and researcher 
TM and the consent process 
• Participant-centered quality measures 
• Assessing individual’s understanding 
• Strategies for improving consent process 
• Case scenarios  
Reading Materials 
Barrett, R. (2005). Quality of informed consent: Measuring understanding among 
participants in oncology clinical trials. Oncology Nursing Forum, 32(4), 751-755.  doi: 
10.1188/05.ONF.751-755. 
 
Pranati, B. (2010). Informed Consent: Are we doing enough? Perspectives in Clinical 
Research, 1(4), 124-127. doi: 10.4103/22229-3485.71769 
 
World Medical Association Declaration of Helsinki-Ethical Principles for Medical 
research Involving Human Subjects (1964). Retrieved from 
http://www.wma.net/en/30publications/10policies/b3/    
 
U.S. Department of Health and Human Services (2004). Code of federal regulations: 
Title 21, section 50.25: Elements of informed consent. Washington, D.C.: U.S. 
Government Printing Office.  
 
Week Four: Recognition and Guidance  
 
Recognizing TM  
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• Vulnerability to TM 
• Motivation, perception, understanding of science 
• Decision making process of subject 
• Interview guide- understanding the subject 
Strategies for correcting misunderstanding 
• Motivation-desire for therapeutic benefit 
• Purpose of clinical trials-gather scientific knowledge 
• Juxtaposing subject’s motivation with scientific aim 
• Integrate “neutral party” in consent process 
• Specific accountability  
Educating peers regarding TM 
• Clinical and research norms 
• TM not just among subjects 
• Clinical Equipoise 
  
Reading Materials 
Scott, Y.H.K., Schrock, L., Wilson, R., Frank, S.A., Holloway, R.G., Kieburtz, K., 
DeVries, R.G. (2009). An approach to evaluating therapeutic misconception. IRB, 31(5), 
7-14. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360887/  
 
Weinfurt, K.P., Castel, L.D., Li, Y., Sulmasy, D.P., Balshem, A.M., Benson, 
A.B., … Meropol NJ.  (2003). The correlation between patient characteristics and 
expectations of benefit from Phase I clinical trials. Cancer: American Cancer Society, 
98(1), 166-75. doi: 10.1002/cncr.11483. Retrieved from: 
http://www.ncbi.nlm.nih.gov/pubmed/12833469 
 
Kass, N., Taylor, H., Fogarty, L., Sugarman, J., Goodman, S.N., Goodwin- Landher, A. 
…Hurwitz, H. (2008). Purpose and benefits of early phase cancer trials: What do 
oncologists say? What do patients hear? Journal of Empirical Research on Human 
Research Ethics: An International Journal, 3(3), 57-68. 
 
Miller, F.G., Rosenstein, D.L., DeRenzo, E.G. (1998). Professional integrity in clinical 
research. Journal of American Medical Association, 280(16), 1449-1454. doi: 
10.100/jama.280.16.1449 
   
Glannon, W. (2006). Phase I oncology trials: Why the therapeutic misconception will not 
go away. Journal of Medical Ethics, 32(5), 252-255.  
 
Week Five: Review and Completion 
 
Summary Review of Information 
• Q & A 




• Teaching about a clinical trial 
• Assessing for TM 
• Correcting misunderstanding 
Self evaluation  
• Knowledge and concepts of TM  
• Ability to assess potential subjects 
Post Survey Completion   







Appendix D Implementation Plan 
Educational Program for RNs on Therapeutic Misconception 
Following the completion of the project and graduation of the DNP student, the 
educational program will be implemented and then evaluated. Each member of the 
development team has agreed to teach the program to the qualified nurses within their 
organization. Studies have found that how educational programs are implemented is 
extremely important and that minor changes in implementation can often make a major 
difference in the size of the programs effects (Gorman-Smith, 2006). The program will be 
implemented by individual team members in a variety of organizational settings allowing 
for slight adjustments to the implementation plan however, the team has agreed that all 
team members will fully implement all aspects of the program. The steps for 
implementation are as follows: 
1. Team members will be responsible for identifying qualified participants 
within their organization and soliciting participation in the education program. RNs 
working in the adult oncology research setting will be invited to participate and made 
aware of the goals of the program and benefits to participation.   
2. The team member is responsible for securing appropriate space for the 
program; the learning environment should be safe and supportive.  
3. Full institutional support is mandatory to the success of the program. 
Together, the DNP and the team member will present to the administration of the 
organization the importance of the education, program plan and syllabus, expected 
outcomes, and costs associated with the program (to be incurred by the institution). It is 
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expected that the research RN will acquire useful knowledge and skills and use them in 
practice; changing practice in the research department. In order to secure successful 
outcomes it is imperative that to garner support from senior leaders and those responsible 
for bringing about the organizational change.   
4. There should be consideration and agreement on compensation of the RNs 
time commitment for the program; whether this will be financial compensation or take 
another form is at the discretion of each organization. Team members, along with the 
DNP, will negotiate and determine the compensation through collaboration with 
administration, clinical leaders, human resources and staff development. Many 
organizations budget for continuing educational activities such as conferences and 
courses and may be willing to provide the compensation for the education.   
5. Employee development and training is the shared responsibility of the 
management and the individual employee. Staff development departments should be 
involved in the understanding of the knowledge and skill that nurses in the oncology 
research department will need in the future. Staff development will assist in the long-term 
goals of the organization regarding TM and the implication of these goals on employee 
development. The pre and post surveys for the TM educational program will be used as 
performance appraisal documents that include descriptions of the areas of knowledge and 
skills that must be learned in order to improve performance. The staff development 
department will be responsible for applying for continuing nurse education credit through 
the state board of nursing.  
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6. The scheduling of the program will be the responsibility of the team member 
and will be achieved through collaboration with the research department and staff 
development.   
7. The cost of the program includes time and materials. Materials include 
scholarly articles for discussion that are available electronically at no cost. The greatest 
expense will be incurred in wages for the RNs participating in the educational program. 
According to the Bureau of Labor Statistics (2013) the medium wage for a research nurse 
is $35.00 per hour. The program is designed to be five hours long. Each participating 
location has an average of twelve research nurses. The cost for RN wages per location is 
estimated to be $2,100.00. Each organization will be responsible for the wages of their 
RNs. The six team members responsible for teaching the program are all salaried 
employees and have agreed to work the additional hours required for the program.        
8. Classroom training will be the responsibility of the team member. Strict 
adherence to the syllabus is required. It is important to remain resolute to the original 
program’s structure and intent. To standardize the educational program, the DNP 
graduate will act as the coordinating principle, communicating with team members before 
and after each scheduled class. 
9. The DNP graduate will monitor sessions to ensure the program’s content is 
being delivered fully and as designed. Problems will be identified and prioritized and 
solutions provided. Content and materials will be revised and logistical issues addressed. 
Monitoring will include a) number of individuals or percent of the eligible population 
who received the education b) number of classroom sessions delivered, how often and 
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over what period of time c) setting in which the education was provided d) extent to 
which sites closely adhere to the program syllabus and e) extent to which deviation from 
the program syllabus is corrected.    











Activity Responsibility of team 
member 
Responsibility of DNP 
Identify participants yes  







Staff development support yes  
Schedule program yes  
Securing cost coverage yes yes 
Classroom training yes  
Monitor sessions for 
problems or concerns 
 yes 








Appendix E Evaluation Plan 
Short and Intermediate Evaluation Plans 
Following the completion of the project and graduation of the DNP student, the 
educational program will be implemented and then evaluated. The purpose of the 
evaluation is to improve the educational effort by improving the program and to measure 
whether the educational program met the stated objectives. For both short term and 
intermediate evaluation of the educational program outcomes will be measured using a 
pre and post survey. A pre and post data collection tool offers a measurement of the 
learning received during the class as a result of comparing what the student knew before 
in a pre-test and after in a post-test (Diem, 2003). The same instrument is used to collect 
data before and after the experience.  
Short Term Evaluation 
At the beginning of the first class, prior to participation in the educational 
program, registered nurses will be asked to complete a survey designed to gauge their 
knowledge of TM. After participating in the educational program, at the completion of 
the final class, the participating nurses will be asked to complete the same survey. Pre 
and post data are collected and analyzed to evaluate whether or not the education 
positively affects the nurses’ knowledge of TM, their ability to recognize TM, and their 
confidence in their ability to correct subjects’ misconceptions regarding the purpose of 
research.    
Surveys will be offered through an on-line domain (such as Survey Monkey). It 
has been determined that use of a previously validated instrument is not possible because 
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no instrument specific to TM education exists. Furthermore, research nurse participation 
in this study necessitates that research nurses have a say in the development and approval 
of the survey instrument. The survey instrument will be developed and vetted through a 
focus group made up of the educational program creators (original team members) and 
research nurses. Whenever possible, items from previously validated and reported 
surveys will be used, modified if necessary and vetted by the focus group. Data will be 
collected and analyzed by the DNP graduate using the SPSS version 17.0 (SPSS Inc., 
Chicago, IL).  A test run of data entry and analysis will be performed to reduce the 
likelihood of unwanted surprises or wasted data. A track bar numbered 0-8 will be used 
to represent continuous data with a higher score corresponding to a higher level of 
knowledge. The main independent variable will be pre-versus-post-TM knowledge. 
Internal reliability will be evaluated using Cronbach’s alpha. Data analysis will be 
performed using a paired sample student’s t-test. The results of a t-test will tell us if the 
difference between the pre and post survey is significant. The short term threshold for 
success will be reached at significance levels less than .05. Results will be disseminated 
to the team members who may then share them with participating RNs and senior leaders 
from the organizations. Results will be used to make decisions regarding the modification 
of the educational program.  
Intermediate Evaluation  
 It is anticipated that the short term evaluation will document evidence that the 
educational program regarding TM for RNs in the adult oncology setting made a positive 
difference. Modifications will be made to the program as needed. Demonstrating that the 
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educational program was affected does not tell us how or why or the role the education 
played. Approximately six months following the implementation of the initial educational 
program, the educational program will be expanded and taught at other institutions. The 
evaluation planning will follow the steps in Table 1. Using the pre and post survey the 
intermediate plan for evaluation will continue to assess whether or not the education 
program made a difference but will also focus on what led to the change. The focus group 
will be responsible for adding questions to the original survey designed to collect 
additional data asking how or why the change came about and what role the education 
played. For example, additional data may answer the questions, “What contribution did 
the educational program make?” or “What factors in the implementation process affected 
the outcome?” Whenever possible, items from previously validated and reported surveys 
will be used, modified if necessary and vetted by the focus group. Data will be collected 
and analyzed by the DNP graduate using the SPSS version 17.0. Internal reliability and 
data analysis will be performed using the same methods as the short term evaluation. The 
intermediate threshold for success will be reached at significance levels less than .05.  
Long Term Evaluation Plan 
The long term evaluation plan will be the sole responsibility of the DNP graduate. 
The long term goal for educating research RNs on TM is to decrease the incidence of TM 
among research subjects. Therefore, the long term evaluation of the educational program 
is designed as a study to measure TM among research subjects before and after the 




During the five weeks that the educational program is being taught to research 
RNs, patients recently enrolled in clinical trials at Sites A, C, and D will be surveyed 
using the Quality of Informed Consent (QuIC) questionnaire (Joffe et al., 2001). The data 
collected will be analyzed. Twelve months later this process will be repeated at sites A, 
C, and D and, within each institution, comparisons made using before education and after 
education data. Data comparisons will be made to assess the long term outcomes of the 
educational program and to determine whether or not there is decreased incidence of TM 
among the subjects enrolled in clinical trials. Success of the educational program will be 
determined by a lower incidence of TM among research subjects after education of the 
research RNs as compared to incidence of TM among research subjects before education 
of the research RNs.  
Sample 
Potential participants in this study will be identified by the affiliated institutions, 
responsible for registering all patients enrolled in clinical trials. Patients 18 years or 
older, enrolled in the previous 14 days, in phase I, II, and III cancer treatment trials, with 
a signed informed consent will be eligible for this study. The QuIC will be mailed to 
adult patients with cancer who recently enrolled in a clinical trial at one of three affiliated 
institutions. 
Instrument 
The QuIC is a standardized measure of assessing the quality of understanding 
among participants in clinical trials. The QuIC questionnaire is based on 13 independent 
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domains derived from the eight basic elements of informed consent specified in federal 
regulations. The questionnaire is written at an eighth-grade reading level and requires an 
estimated seven minutes to complete. The QuIC consists of three parts. Part A contains 
20 questions and measures subject’s knowledge of the basic elements of informed 
consent. Part B contains 14 questions and measures the understanding of the important 
elements of the specific trial in which subjects consented to participate. Part C covers 
subject’s perception of the informed consent process, demographic characteristics, and 
previous participation in research. Content validity of the questionnaire was established 
after review by two independent panels of experts in the fields of bioethics, statistics, 
oncology, and clinical trial design (Joffe, et al., 2001). Test re-test reliability was 
examined with intraclass correlation coefficients of 0.66 for tests of objective 
understanding and 0.77 for tests of subjective understanding (Joffe, et al., 2001).  
Variable 
 The primary objective of this study is to measure how well newly enrolled trial 
subjects understand the trial in which they agreed to participate. This variable will be 
measured before and after research RNs participate in an educational program with 
comparisons of before and after data made within each institution.  
Data Analysis 
QuIC Data Analysis 
Returned questionnaires will be examined for eligibility and completeness before 
being included in the study. Data will be analyzed using SPSS version 17.0 (SPSS Inc., 
Chicago, IL). The data will be summarized using descriptive statistics, including 
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frequency distribution, measures of central tendency, and dispersion. The QuIC 
questionnaire will be scored in two steps. Responses to individual questions in Part A 
will be combined in a knowledge score, ranging from 0 (least) to 100. Responses to Part 
B will be averaged and normalized for a possible range of 0-100, generating a self-
assessment score. Bivariate correlations will be performed to determine the direction and 
magnitude of any relationships.   
Study phase one (pre) and phase two (post) Comparison Analysis  
Data will be analyzed using SPSS version 17.0 (SPSS Inc., Chicago, IL). The 
main independent variable will be pre-versus-post- scores from Part B of the QuIC- the 
understanding of the important elements of the specific trial in which subjects consented 
to participate. Data analysis will be performed using a t-test to compare the two means 
within each institution. The long term threshold for success will be reached at a 
significance level of α < 0.05.  
Results will be disseminated to the original team members who may then share 
them with participating RNs and senior leaders from the organizations. Results will be 







Appendix F: Quality of Informed Consent Survey (QuIC)  
Part A 
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Part B 
 
